8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 25, 2026·SEC
PTC Therapeutics, Inc.(PTCT)Earnings, Financials & Key Ratios
PTCT•NASDAQ
10.2× P/E·Price updated Jun 19, 2026
AboutPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Show more
- Revenue$1.73B+114.5%
- EBITDA$895M+494.6%
- Net Income$683M+287.9%
- EPS (Diluted)7.78+264.5%
- Gross Margin95.85%+3.2%
- EBITDA Margin51.73%+283.9%
- Operating Margin49.49%+232.0%
- Net Margin39.44%+187.6%
PTCT Key Insights
PTC Therapeutics, Inc. (PTCT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 40.6% free cash flow margin
- ✓Strong 5Y sales CAGR of 35.4%
✗Weaknesses
- ✗Shares diluted 14.9% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PTCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTCT Price & Volume
PTC Therapeutics, Inc. (PTCT) stock price & volume — 10-year historical chart
Loading chart...
PTCT Growth Metrics
PTC Therapeutics, Inc. (PTCT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years46.99%
5 Years35.37%
3 Years35.3%
TTM-53.34%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-131.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-135.85%
Return on Capital
10 Years-19.61%
5 Years-11.64%
3 Years-1.03%
Last Year55.86%
PTCT Recent Earnings
PTC Therapeutics, Inc. (PTCT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.03+93.3%
$0.45
Rev
$273M+25.4%
$217M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$1.67-695.2%
$0.21
Rev
$165M-41.1%
$279M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.20+116.8%
$1.19
Rev
$211M-25.0%
$281M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.83+22.4%
$1.07
Rev
$179M-6.6%
$191M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.03vs $0.45+93.3% | $273Mvs $217M+25.4% |
| Q1 2026 | Feb 19, 2026 | $1.67vs $0.21-695.2% | $165Mvs $279M-41.1% |
| Q4 2025 | Nov 4, 2025 | $0.20vs $1.19+116.8% | $211Mvs $281M-25.0% |
| Q3 2025 | Aug 7, 2025 | $0.83vs $1.07+22.4% | $179Mvs $191M-6.6% |
Based on last 12 quarters of dataView full earnings history →
PTCT Peer Comparison
PTC Therapeutics, Inc. (PTCT) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RYTM | 6.63B | 96.79 | -31.12 | 45.83% | -93.84% | -204.35% | 1.77 |
Compare PTCT vs Peers
PTC Therapeutics, Inc. (PTCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTCT Income Statement
PTC Therapeutics, Inc. (PTCT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 194.39M | 264.73M | 306.98M | 380.77M | 538.59M | 698.8M | 937.82M | 806.78M | 1.73B | 827.11M |
Revenue Growth % | 135.04% | 36.19% | 15.96% | 24.04% | 41.45% | 29.75% | 34.2% | -13.97% | 114.51% | -53.34% |
Cost of Goods Sold | 4.58M | 12.67M | 12.13M | 18.94M | 32.33M | 44.68M | 65.49M | 57.4M | 71.75M | 183.27M |
COGS % of Revenue | 2.35% | 4.79% | 3.95% | 4.97% | 6% | 6.39% | 6.98% | 7.11% | 4.15% | - |
Gross Profit | 189.81M▲ 0% | 252.06M▲ 32.8% | 294.85M▲ 17.0% | 361.82M▲ 22.7% | 506.26M▲ 39.9% | 654.12M▲ 29.2% | 872.34M▲ 33.4% | 749.38M▼ 14.1% | 1.66B▲ 121.4% | 643.84M▲ 0% |
Gross Margin % | 97.65% | 95.21% | 96.05% | 95.03% | 94% | 93.61% | 93.02% | 92.89% | 95.85% | 77.84% |
Gross Profit Growth % | 643.45% | 32.79% | 16.97% | 22.72% | 39.92% | 29.21% | 33.36% | -14.09% | 121.37% | - |
Operating Expenses | 254.11M | 348.41M | 536M | 793.59M | 880.71M | 1.1B | 1.31B | 1.05B | 802.39M | 711.52M |
OpEx % of Revenue | 130.72% | 131.61% | 174.61% | 208.42% | 163.52% | 157.63% | 139.88% | 130.39% | 46.36% | - |
Selling, General & Admin | 121.27M | 153.55M | 202.54M | 245.16M | 285.77M | 326M | 332.54M | 300.91M | 347.14M | 355.96M |
SG&A % of Revenue | 62.38% | 58% | 65.98% | 64.39% | 53.06% | 46.65% | 35.46% | 37.3% | 20.06% | - |
Research & Development | 117.46M | 171.98M | 257.45M | 477.64M | 540.68M | 651.5M | 666.56M | 534.48M | 455.25M | 447.15M |
R&D % of Revenue | 60.42% | 64.96% | 83.87% | 125.44% | 100.39% | 93.23% | 71.08% | 66.25% | 26.3% | - |
Other Operating Expenses | -1.28M | 129K | 76.01M | 70.78M | 54.25M | 124.04M | 312.74M | 216.56M | 0 | -1000K |
Operating Income | -64.29M▲ 0% | -115.69M▼ 79.9% | -241.16M▼ 108.5% | -431.77M▼ 79.0% | -374.44M▲ 13.3% | -447.41M▼ 19.5% | -439.5M▲ 1.8% | -302.57M▲ 31.2% | 856.51M▲ 383.1% | -67.68M▲ 0% |
Operating Margin % | -33.07% | -43.7% | -78.56% | -113.39% | -69.52% | -64.03% | -46.86% | -37.5% | 49.49% | -8.18% |
Operating Income Growth % | 51.32% | -79.94% | -108.46% | -79.04% | 13.28% | -19.49% | 1.77% | 31.16% | 383.08% | - |
EBITDA | -46.61M | -89.6M | -208.98M | -388.28M | -310.31M | -318.57M | -202.91M | -226.91M | 895.32M | -20.67M |
EBITDA Margin % | -23.98% | -33.84% | -68.08% | -101.97% | -57.61% | -45.59% | -21.64% | -28.13% | 51.73% | -2.5% |
EBITDA Growth % | 63.8% | -92.23% | -133.24% | -85.8% | 20.08% | -2.66% | 36.31% | -11.83% | 494.58% | -102.79% |
D&A (Non-Cash Add-back) | 17.68M | 26.09M | 32.18M | 43.49M | 64.13M | 128.84M | 236.59M | 75.66M | 38.81M | 47.01M |
EBIT | -64.29M | -115.56M | -227.44M | -346.58M | -432.32M | -496.62M | -566.93M | -196.13M | 848.85M | -69.19M |
Net Interest Income | -12.09M | -12.55M | -12.49M | -56.35M | -86.02M | -90.87M | -129.18M | -166.99M | -152.23M | -69.11M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 12.09M | 12.55M | 12.49M | 56.35M | 86.02M | 90.87M | 129.18M | 166.99M | 152.23M | 69.11M |
Other Income/Expense | -13.37M | -12.43M | 1.23M | 28.84M | -143.9M | -140.08M | -256.61M | -60.55M | -159.89M | -167.99M |
Pretax Income | -77.67M▲ 0% | -128.11M▼ 65.0% | -239.93M▼ 87.3% | -402.93M▼ 67.9% | -518.34M▼ 28.6% | -587.49M▼ 13.3% | -696.11M▼ 18.5% | -363.12M▲ 47.8% | 696.62M▲ 291.8% | -235.67M▲ 0% |
Pretax Margin % | -39.95% | -48.39% | -78.16% | -105.82% | -96.24% | -84.07% | -74.23% | -45.01% | 40.25% | -28.49% |
Income Tax | 1.33M | -29K | 11.65M | 35.23M | 5.56M | -28.47M | -69.51M | 176K | 13.97M | -48.94M |
Effective Tax Rate % | -1.72% | 0.02% | -4.86% | -8.74% | -1.07% | 4.85% | 9.98% | -0.05% | 2.01% | 20.77% |
Net Income | -79M▲ 0% | -128.08M▼ 62.1% | -251.58M▼ 96.4% | -438.16M▼ 74.2% | -523.9M▼ 19.6% | -559.02M▼ 6.7% | -626.6M▼ 12.1% | -363.3M▲ 42.0% | 682.64M▲ 287.9% | -186.73M▲ 0% |
Net Margin % | -40.64% | -48.38% | -81.95% | -115.07% | -97.27% | -80% | -66.81% | -45.03% | 39.44% | -22.58% |
Net Income Growth % | 44.41% | -62.13% | -96.42% | -74.17% | -19.57% | -6.7% | -12.09% | 42.02% | 287.9% | -131.39% |
Net Income (Continuing) | -79M | -128.08M | -251.58M | -438.16M | -523.9M | -559.02M | -626.6M | -363.3M | 682.64M | -186.73M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.02▲ 0% | -2.75▼ 36.1% | -4.27▼ 55.3% | -6.64▼ 55.5% | -7.43▼ 11.9% | -7.79▼ 4.8% | -8.37▼ 7.4% | -4.73▲ 43.5% | 7.78▲ 264.5% | -2.26▲ 0% |
EPS Growth % | 51.56% | -36.14% | -55.27% | -55.5% | -11.9% | -4.85% | -7.45% | 43.49% | 264.48% | -135.85% |
EPS (Basic) | -2.02 | -2.75 | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 8.58 | - |
Diluted Shares Outstanding | 39.18M | 46.58M | 58.86M | 66.03M | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M | 82.52M |
Basic Shares Outstanding | 39.11M | 46.58M | 58.86M | 66.03M | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M | 82.52M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PTCT Balance Sheet
PTC Therapeutics, Inc. (PTCT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 249.06M | 320.86M | 779.28M | 1.23B | 954.37M | 693.78M | 1.22B | 1.37B | 2.27B | 2.25B |
Cash & Short-Term Investments | 191.25M | 227.59M | 686.56M | 1.1B | 773.38M | 410.7M | 876.74M | 1.14B | 1.95B | 1.89B |
Cash Only | 191.25M | 227.59M | 288.03M | 208.81M | 189.72M | 279.83M | 594M | 779.71M | 984.65M | 833.99M |
Short-Term Investments | 0 | 0 | 398.54M | 894.84M | 583.66M | 130.87M | 282.74M | 359.99M | 960.72M | 1.06B |
Accounts Receivable | 40.39M | 67.91M | 55.54M | 69.93M | 110.45M | 155.61M | 160.82M | 158.55M | 181.62M | 219.92M |
Days Sales Outstanding | 75.85 | 93.63 | 66.03 | 67.03 | 74.85 | 81.28 | 62.59 | 71.73 | 38.3 | 88.34 |
Inventory | 10.75M | 16.12M | 19.29M | 18.7M | 15.86M | 21.81M | 30.58M | 23.19M | 79.65M | 75.57M |
Days Inventory Outstanding | 857.59 | 464.3 | 580.06 | 360.28 | 179.02 | 178.16 | 170.43 | 147.49 | 405.14 | 120.48 |
Other Current Assets | 6.67M | 9.25M | 0 | 0 | 0 | 105.66M | 150.49M | 44.09M | 67.31M | 66.05M |
Total Non-Current Assets | 142.59M | 798.37M | 844.5M | 976.53M | 983.69M | 1.01B | 677.07M | 339.49M | 637.3M | 615.1M |
Property, Plant & Equipment | 8.38M | 12.69M | 35.24M | 118.24M | 130.01M | 175.02M | 178.99M | 117.66M | 135.42M | 129.43M |
Fixed Asset Turnover | 23.21x | 20.86x | 8.71x | 3.22x | 4.14x | 3.99x | 5.24x | 6.86x | 12.78x | 6.41x |
Goodwill | 0 | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M | 82.34M |
Intangible Assets | 132.99M | 701.03M | 710.5M | 715.33M | 724.84M | 705.89M | 379.5M | 118.79M | 388.75M | 380.68M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.69M | 43.82M |
Other Non-Current Assets | 1.22M | 2.3M | 16.41M | 60.62M | 46.5M | 48.58M | 36.25M | 20.7M | 4.62M | 6.2M |
Total Assets | 391.65M▲ 0% | 1.12B▲ 185.8% | 1.62B▲ 45.1% | 2.21B▲ 36.0% | 1.94B▼ 12.2% | 1.71B▼ 12.0% | 1.9B▲ 11.1% | 1.71B▼ 10.1% | 2.91B▲ 70.7% | 2.87B▲ 0% |
Asset Turnover | 0.50x | 0.24x | 0.19x | 0.17x | 0.28x | 0.41x | 0.49x | 0.47x | 0.59x | 0.30x |
Asset Growth % | 45.41% | 185.77% | 45.08% | 36% | -12.24% | -11.99% | 11.14% | -10.06% | 70.75% | 159.76% |
Total Current Liabilities | 82.05M | 166.8M | 235.86M | 277.33M | 509.35M | 406.24M | 603.1M | 580.98M | 968.43M | 923.6M |
Accounts Payable | 15.28M | 6M | 10.32M | 18.66M | 23.03M | 27.27M | 6.04M | 17.27M | 45.49M | 25.48M |
Days Payables Outstanding | 1.22K | 172.88 | 310.53 | 359.66 | 260.05 | 222.77 | 33.69 | 109.85 | 231.38 | 66.77 |
Short-Term Debt | 0 | 11.67M | 20M | 0 | 208.83M | 72.15M | 194.31M | 257.82M | 302.12M | 305.01M |
Deferred Revenue (Current) | 3.94M | 3.72M | 8.24M | 4.15M | 0 | 1.35M | 801K | 5.5M | 2.04M | 13.99M |
Other Current Liabilities | 45.12M | 117.78M | 120.16M | 129.89M | 118.86M | 126.46M | 139.82M | 120.22M | 540.37M | 558.76M |
Current Ratio | 3.04x | 1.92x | 3.30x | 4.44x | 1.87x | 1.71x | 2.02x | 2.35x | 2.35x | 2.44x |
Quick Ratio | 2.90x | 1.83x | 3.22x | 4.37x | 1.84x | 1.65x | 1.97x | 2.31x | 2.27x | 2.36x |
Cash Conversion Cycle | -285.25 | 385.05 | 335.57 | 67.65 | -6.18 | 36.67 | 199.33 | 109.38 | 212.07 | 142.05 |
Total Non-Current Liabilities | 153.17M | 601.7M | 793.6M | 1.45B | 1.43B | 1.65B | 2.11B | 2.22B | 2.15B | 2.13B |
Long-Term Debt | 144.97M | 141.35M | 293.86M | 309.14M | 956.59M | 1.26B | 1.9B | 2.11B | 93.58M | 0 |
Capital Lease Obligations | 0 | 0 | 9.02M | 102.55M | 93.67M | 119.53M | 114.81M | 90.52M | 96.58M | 381.05M |
Deferred Tax Liabilities | -3.94M | 122.03M | 130.86M | 136.74M | 137.11M | 102.83M | 55.91M | 0 | 12.48M | 12.48M |
Other Non-Current Liabilities | 243K | 328.6M | 356.44M | 900.53M | 239.9M | 166.64M | 36.44M | 22.23M | 1.95B | 2.04B |
Total Liabilities | 235.22M | 768.5M | 1.03B | 1.73B | 1.94B | 2.05B | 2.71B | 2.8B | 3.12B | 3.05B |
Total Debt | 144.97M | 153.01M | 328.03M | 420.44M | 1.27B | 1.46B | 2.23B | 2.47B | 492.28M | 395.09M |
Net Debt | -46.27M | -74.57M | 40M | 211.63M | 1.08B | 1.18B | 1.64B | 1.69B | -492.37M | -438.9M |
Debt / Equity | 0.93x | 0.44x | 0.55x | 0.87x | 882.73x | - | - | - | - | -2.19x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 0.55x | -19.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.55x | 21.23x |
Interest Coverage | -5.32x | -9.20x | -18.21x | -6.15x | -5.03x | -5.47x | -4.39x | -1.17x | 5.58x | -1.00x |
Total Equity | 156.44M▲ 0% | 350.73M▲ 124.2% | 594.33M▲ 69.5% | 481.98M▼ 18.9% | 1.44M▼ 99.7% | -347.09M▼ 24236.7% | -818.55M▼ 135.8% | -1.1B▼ 34.1% | -205.31M▲ 81.3% | -180.47M▲ 0% |
Equity Growth % | 30.82% | 124.2% | 69.46% | -18.9% | -99.7% | -24236.72% | -135.84% | -34.15% | 81.3% | 248.31% |
Book Value per Share | 3.99 | 7.53 | 10.10 | 7.30 | 0.02 | -4.84 | -10.94 | -14.29 | -2.32 | -2.19 |
Total Shareholders' Equity | 156.44M | 350.73M | 594.33M | 481.98M | 1.44M | -347.09M | -818.55M | -1.1B | -205.31M | -180.47M |
Common Stock | 42K | 51K | 62K | 70K | 71K | 72K | 75K | 77K | 80K | 81K |
Retained Earnings | -814.11M | -938.92M | -1.19B | -1.63B | -2.1B | -2.66B | -3.28B | -3.65B | -2.96B | -2.97B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 3.97M | 1.46M | -10.58M | -60.96M | -24.28M | 4.8M | -1.28M | -25.89M | 10.5M | 8.47M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PTCT Cash Flow Statement
PTC Therapeutics, Inc. (PTCT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.06M | -27.64M | -98.64M | -194.07M | -251.33M | -356.65M | -158.42M | -107.69M | 711.2M | -217.95M |
Operating CF Margin % | -5.18% | -10.44% | -32.13% | -50.97% | -46.66% | -51.04% | -16.89% | -13.35% | 41.09% | - |
Operating CF Growth % | 90.28% | -174.68% | -256.86% | -96.75% | -29.51% | -41.91% | 55.58% | 32.02% | 760.42% | -88.77% |
Net Income | -79M | -128.08M | -251.58M | -438.16M | -523.9M | -559.02M | -626.6M | -363.3M | 682.64M | -186.73M |
Depreciation & Amortization | 17.68M | 26.09M | 32.18M | 84.87M | 64.13M | 128.84M | 236.59M | 75.66M | 38.81M | 31.59M |
Stock-Based Compensation | 30.56M | 33.25M | 42.13M | 70.33M | 103.51M | 110.33M | 131.21M | 74.61M | 0 | 37.97M |
Deferred Taxes | 199K | -490K | 8.83M | 5.87M | 377K | -34.28M | -46.93M | -55.91M | -3K | -5K |
Other Non-Cash Items | 7.27M | 27.38M | 49.37M | 46.11M | 128.33M | 82.81M | 151.32M | 58.7M | 42.3M | 20.4M |
Working Capital Changes | 13.23M | 14.21M | 20.43M | 36.91M | -23.79M | -85.33M | -4M | 102.54M | -52.56M | -121.18M |
Change in Receivables | -12.2M | -29.59M | 11.53M | -10.48M | -44.99M | -48.47M | -1.54M | 1.73M | -10.15M | -2.75M |
Change in Inventory | -6.45M | -5.82M | -3.46M | 1.84M | 1.8M | -6.67M | -8.18M | 6.16M | -53.9M | -53.44M |
Change in Payables | 24.01M | 43.11M | 13.75M | 53.59M | 23.41M | 27.54M | 0 | 0 | 0 | 0 |
Cash from Investing | 13.12M | -42.61M | -387.24M | -561.55M | 219.18M | 290.18M | -176.74M | 44.18M | -861.98M | -771.36M |
Capital Expenditures | -3.1M | -15.53M | -45.44M | -55.98M | -85.33M | -152.46M | -28.44M | -6.5M | -300.01M | -43.41M |
CapEx % of Revenue | 1.6% | 5.87% | 14.8% | 14.7% | 15.84% | 21.82% | 3.03% | 0.81% | 17.34% | 5.25% |
Acquisitions | -77.16M | -48.89M | -4M | 38.13M | 57.12M | 128.44M | 0 | 0 | 70K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 16.22M | 13.38M | 0 | -38.13M | -57.12M | -128.44M | -92.18M | 110.31M | 0 | -255.43M |
Cash from Financing | 44.22M | 131.57M | 613.21M | 668.72M | 20.88M | 167.95M | 646.4M | 255.87M | 331.09M | 328.09M |
Debt Issued (Net) | 40M | 0 | 267.6M | -46.16M | -2.22M | 148.72M | -301.38M | -1.49M | 0 | 0 |
Equity Issued (Net) | 0 | 117.92M | 323.76M | 28.09M | 23.1M | 50M | 0 | 0 | 99.05M | 68.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 4.22M | 13.65M | 21.85M | 686.78M | 0 | -30.77M | 947.78M | 257.36M | 232.05M | 259.18M |
Net Change in Cash | 53.47M▲ 0% | 57.71M▲ 7.9% | 126.03M▲ 118.4% | -79.22M▼ 162.9% | -19.09M▲ 75.9% | 98.71M▲ 617.0% | 314.36M▲ 218.5% | 185.03M▼ 41.1% | 204.94M▲ 10.8% | -646.19M▲ 0% |
Free Cash Flow | -13.16M▲ 0% | -43.17M▼ 227.9% | -144.08M▼ 233.7% | -250.05M▼ 73.6% | -336.66M▼ 34.6% | -509.11M▼ 51.2% | -279.04M▲ 45.2% | -181.94M▲ 34.8% | 702.34M▲ 486.0% | -228.96M▲ 0% |
FCF Margin % | -6.77% | -16.31% | -46.93% | -65.67% | -62.51% | -72.86% | -29.75% | -22.55% | 40.58% | -27.68% |
FCF Growth % | 87.5% | -227.95% | -233.74% | -73.55% | -34.64% | -51.22% | 45.19% | 34.8% | 486.03% | -133.71% |
FCF per Share | -0.34 | -0.93 | -2.45 | -3.79 | -4.78 | -7.10 | -3.73 | -2.37 | 7.95 | -2.77 |
FCF Conversion (FCF/Net Income) | 0.13x | 0.22x | 0.39x | 0.44x | 0.48x | 0.64x | 0.25x | 0.30x | 1.04x | 1.23x |
Interest Paid | 6.27M | 7.77M | 7.69M | 9.8M | 9.59M | 18.46M | 36.13M | 5.82M | 0 | 0 |
Taxes Paid | 1.1M | 1.58M | 2.11M | 26.4M | 7.71M | 4.92M | 14.15M | 17.55M | 0 | 36.15M |
PTCT Key Ratios
PTC Therapeutics, Inc. (PTCT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -57.24% | -50.51% | -53.24% | -81.42% | -216.75% | - | - | - | - | 99.84% |
Return on Invested Capital (ROIC) | -100.15% | -44.92% | -39.73% | -48.77% | -31.65% | -35.03% | -39.93% | -32.19% | - | 8.2% |
Gross Margin | 97.65% | 95.21% | 96.05% | 95.03% | 94% | 93.61% | 93.02% | 92.89% | 95.85% | 77.84% |
Net Margin | -40.64% | -48.38% | -81.95% | -115.07% | -97.27% | -80% | -66.81% | -45.03% | 39.44% | -22.58% |
Debt / Equity | 0.93x | 0.44x | 0.55x | 0.87x | 882.73x | - | - | - | - | -2.19x |
Interest Coverage | -5.32x | -9.20x | -18.21x | -6.15x | -5.03x | -5.47x | -4.39x | -1.17x | 5.58x | -1.00x |
FCF Conversion | 0.13x | 0.22x | 0.39x | 0.44x | 0.48x | 0.64x | 0.25x | 0.30x | 1.04x | 1.23x |
Revenue Growth | 135.04% | 36.19% | 15.96% | 24.04% | 41.45% | 29.75% | 34.2% | -13.97% | 114.51% | -53.34% |
Related:PTCT Dividend History·PTCT Revenue History·PTCT Price History·PTCT P/E History·PTCT Financial Ratios·PTCT Institutional Holders
PTCT SEC Filings & Documents
PTC Therapeutics, Inc. (PTCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
PTCT Frequently Asked Questions
PTC Therapeutics, Inc. (PTCT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
PTC Therapeutics, Inc. (PTCT) reported $827.1M in revenue for fiscal year 2025. This represents a 736% increase from $99.0M in 2011.
PTC Therapeutics, Inc. (PTCT) grew revenue by 114.5% over the past year. This is strong growth.
PTC Therapeutics, Inc. (PTCT) reported a net loss of $186.7M for fiscal year 2025.
Dividend & Returns
PTC Therapeutics, Inc. (PTCT) had negative free cash flow of $229.0M in fiscal year 2025, likely due to heavy capital investments.